FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Despite holdouts, Roche has Ventana

Tools

It's in the bag. Roche has officially acquired 70.5 percent of Ventana's shares, enough to wrap up the acquisition. But Roche has extended its $3.4 billion tender offer to February 15 in an attempt to grab more shares, because if it can boost that percentage above 90, the closing will be easier to manage. Last month, Roche upped its offer to $89.50 per share from $75.

Among the holdouts are Ventana Chairman Jack Schuler and Vice Chairman John Patience--who together own 11 percent of the shares--as well as investor Larry Feinberg, an investor with 7.81 percent who's a longtime backer of the two men. Feinberg told the Financial Times that the board members wanted $95 per share, but might settle for $93. "My sense is probably there is a good chance that this goes a little higher," Feinberg said.

Roche, however, says it's sticking to the same cash price as the other shareholders got, and whatever shares aren't tendered will be converted to cash rights. In case that wasn't clear, Roche states that the company "has sufficient voting power to approve the merger without the affirmative vote of any other Ventana shareholder." Touché.

- check out Roche's release
- read the article in the Houston Chronicle
- see this behind-the-scenes report from the Financial Times

Related Articles:
Big Ventana owners could nix deal. Report
Roche nabs the $3.4B Ventana prize. Report
Roche still confident on Ventana buyout. Report
Roche asks, Ventana says no...again. Report
Ventana spurns Roche's $3B hostile takeover bid. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:

More stories about Roche   Ventana   hostile takeover   Mergers and Acquisitions